Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ruxolitinib + methylprednisolone + lenalidomide
- Development stage
- Unknown
- Lead developer
- Oncotherapeutics
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
**Ruxolitinib + methylprednisolone + lenalidomide** is an investigational three-drug combination therapy for relapsed/refractory multiple myeloma and related hematological malignancies. Ruxolitinib is a selective inhibitor of Janus kinase 1 and 2 (JAK1/JAK2) that modulates inflammatory and immune signaling. Methylprednisolone is a synthetic glucocorticoid steroid with immunosuppressive and anti-inflammatory actions. Lenalidomide is an immunomodulatory agent (IMiD) with anti-angiogenic, anti-proliferative, and immune-activating properties, primarily acting through modulation of cereblon to facilitate targeted protein degradation, and is a derivative of thalidomide. The rationale for combining these agents is to overcome lenalidomide and steroid resistance in heavily treated multiple myeloma patients, leveraging the synergistic anti-myeloma activity observed in preclinical and early clinical trials. This combination is still in early-stage clinical development for patients with relapsed/refractory multiple myeloma who have experienced disease progression on prior regimens[4][7][9].
- Brand names
- JakafiRevlimidMedrol
- Other names
- ruxolitinib + methylprednisolone + lenalidomide
02
Targets
Beyond the preview
Go deeper on ruxolitinib + methylprednisolone + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ruxolitinib + methylprednisolone + lenalidomide.